Publications by authors named "Pei-Ran Ho"

Claim this Profile
T
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
Robert J Fox, Bruce A C Cree, Jérôme de Sèze, Ralf Gold, Hans-Peter Hartung, Nicholas Belviso, Pei-Ran Ho

Neurology· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits of early treatment with natalizumab: a real-world study.
Daniel Ontaneda, Ellen M Mowry, Scott D Newsome, Robert T Naismith, Jacqueline Nicholas, Pei-Ran Ho

Mult Scler Relat Disord· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).
Helmut Butzkueven, Ludwig Kappos, Tim Spelman, Maria Trojano, Heinz Wiendl, Pei-Ran Ho

Ther Adv Neurol Disord· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
Heinz Wiendl, Tim Spelman, Helmut Butzkueven, Ludwig Kappos, Maria Trojano, Pei-Ran Ho

Mult Scler· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri Observational Program (TOP).
Helmut Butzkueven, Maria Trojano, Ludwig Kappos, Tim Spelman, Heinz Wiendl, Pei-Ran Ho

Mult Scler· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.
Ih Chang, Kumar Kandadi Muralidharan, Nolan Campbell, Pei-Ran Ho

J Clin Pharmacol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.
Helmut Butzkueven, Stephanie Licata, Douglas Jeffery, Douglas L Arnold, Massimo Filippi, Pei-Ran Ho

BMJ Open· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl, Maria Trojano, Tim Spelman, Pei-Ran Ho

J Neurol Neurosurg Psychiatry· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis.
John Foley, Cynthia Carrillo-Infante, Jonathan Smith, Karleyton Evans, Pei-Ran Ho

Mult Scler Relat Disord· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
Lana Zhovtis Ryerson, John Foley, Ih Chang, Ilya Kister, Gary Cutter, Christophe Hotermans, Pei-Ran Ho

Neurology· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The risk of PML from natalizumab - Authors' reply.
Pei-Ran Ho, Nolan Campbell, Ih Chang

Lancet Neurol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Raju Kapoor, Pei-Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin

Lancet Neurol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Pei-Ran Ho, Harold Koendgen, Nolan Campbell, Bill Haddock, Sandra Richman

Lancet Neurol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
Tatiana Plavina, Kumar Kandadi Muralidharan, Geoffrey Kuesters, Daniel Mikol, Karleyton Evans, Pei-Ran Ho

Neurology· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.
Kumar Kandadi Muralidharan, Deb Steiner, Diogo Amarante, Pei-Ran Ho, Dan Mikol

J Pharmacokinet Pharmacodyn· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay.
Denise Campagnolo, Qunming Dong, Lily Lee, Pei-Ran Ho, Diogo Amarante

J Neurovirol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for characterizing the risk of PML in natalizumab-treated patients.
Harold Koendgen, Pei-Ran Ho, Ih Chang

Mult Scler Relat Disord· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
Bente L Langdahl, Christence Stubbe Teglbjærg, Pei-Ran Ho, Roland Chapurlat, Edward Czerwinski

J Clin Endocrinol Metab· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
Santiago Palacios, Irene Agodoa, Sydney Bonnick, Joop P Van den Bergh, Irene Ferreira, Pei-Ran Ho

J Clin Endocrinol Metab· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
Akhila Balasubramanian, Laura L Tosi, Joseph M Lane, Douglas R Dirschl, Pei-Ran Ho

J Bone Joint Surg Am· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial.
Jacques P Brown, Christian Roux, Ove Törring, Pei-Ran Ho, Jens-Erik Beck Jensen

J Bone Miner Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.
Silvano Adami, Cesar Libanati, Steven Boonen, Steven R Cummings, Pei-Ran Ho

J Bone Joint Surg Am· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis